STAT3 and osteosarcoma: The introduction of additional ferroptosis inducers or STAT3 inhibitors has been demonstrated to increase the susceptibility of osteosarcoma cells to cisplatin, offering a potential approach to treating drug‐resistant osteosarcoma (Liu and Wang 2019).